Emergent Biosolutions Stock Performance
| EBS Stock | USD 5.73 0.01 0.17% |
The firm shows a Beta (market volatility) of 1.09, which means a somewhat significant risk relative to the market. Emergent Biosolutions returns are very sensitive to returns on the market. As the market goes up or down, Emergent Biosolutions is expected to follow. At this point, Emergent Biosolutions has a negative expected return of -0.54%. Please make sure to confirm Emergent Biosolutions' total risk alpha, as well as the relationship between the kurtosis and day typical price , to decide if Emergent Biosolutions performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Emergent Biosolutions has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's fundamental drivers remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Actual Historical Performance (%)
One Day Return 0.17 | Five Day Return (1.21) | Year To Date Return (44.21) | Ten Year Return (79.25) | All Time Return (51.03) |
1 | Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 | 01/08/2025 |
2 | Disposition of 918 shares by Jessica Perl of Emergent Biosolutions at 10.0 subject to Rule 16b-3 | 02/07/2025 |
3 | Disposition of 683 shares by Richard Lindahl of Emergent Biosolutions at 7.48 subject to Rule 16b-3 | 02/28/2025 |
4 | Disposition of 313 shares by Coleen Glessner of Emergent Biosolutions at 7.48 subject to Rule 16b-3 | 03/03/2025 |
5 | Emergent BioSolutions Inc Q4 2024 Earnings Call Highlights Strategic Advancements Amid ... | 03/04/2025 |
6 | Is Emergent BioSolutions Weighed On By Its Debt Load | 03/05/2025 |
7 | Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International | 03/10/2025 |
8 | Emergent BioSolutions to invest in Rocketvax for vaccine developments | 03/12/2025 |
9 | Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Prog... | 03/13/2025 |
10 | Emergent BioSolutions Announces Approximately 27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Produc... | 03/18/2025 |
11 | Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 | 03/20/2025 |
12 | Benign Growth For Emergent BioSolutions Inc. Underpins Stocks 31 percent Plummet | 03/21/2025 |
| Begin Period Cash Flow | 111.7 M |
Emergent |
Emergent Biosolutions Relative Risk vs. Return Landscape
If you would invest 842.00 in Emergent Biosolutions on December 25, 2024 and sell it today you would lose (269.00) from holding Emergent Biosolutions or give up 31.95% of portfolio value over 90 days. Emergent Biosolutions is generating negative expected returns assuming volatility of 4.7048% on return distribution over 90 days investment horizon. In other words, 42% of stocks are less volatile than Emergent, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Emergent Biosolutions Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Emergent Biosolutions' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Emergent Biosolutions, and traders can use it to determine the average amount a Emergent Biosolutions' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1148
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | EBS |
Estimated Market Risk
| 4.7 actual daily | 41 59% of assets are more volatile |
Expected Return
| -0.54 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Emergent Biosolutions is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Emergent Biosolutions by adding Emergent Biosolutions to a well-diversified portfolio.
Emergent Biosolutions Fundamentals Growth
Emergent Stock prices reflect investors' perceptions of the future prospects and financial health of Emergent Biosolutions, and Emergent Biosolutions fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Emergent Stock performance.
| Return On Equity | -0.35 | ||||
| Return On Asset | -0.0422 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 875.01 M | ||||
| Shares Outstanding | 54.18 M | ||||
| Price To Earning | 1.67 X | ||||
| Price To Book | 0.64 X | ||||
| Price To Sales | 0.30 X | ||||
| Revenue | 1.01 B | ||||
| Gross Profit | 290.1 M | ||||
| EBITDA | 36.9 M | ||||
| Net Income | (190.6 M) | ||||
| Cash And Equivalents | 642.6 M | ||||
| Cash Per Share | 7.28 X | ||||
| Total Debt | 663.7 M | ||||
| Debt To Equity | 0.56 % | ||||
| Current Ratio | 3.92 X | ||||
| Book Value Per Share | 9.40 X | ||||
| Cash Flow From Operations | 58.7 M | ||||
| Earnings Per Share | (11.22) X | ||||
| Market Capitalization | 540.22 M | ||||
| Total Asset | 1.39 B | ||||
| Retained Earnings | (212.4 M) | ||||
| Working Capital | 436.3 M | ||||
| Current Asset | 537.41 M | ||||
| Current Liabilities | 99.61 M | ||||
About Emergent Biosolutions Performance
Assessing Emergent Biosolutions' fundamental ratios provides investors with valuable insights into Emergent Biosolutions' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Emergent Biosolutions is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 113.8 B | 119.5 B | |
| Return On Tangible Assets | (0.21) | (0.20) | |
| Return On Capital Employed | (0.09) | (0.08) | |
| Return On Assets | (0.14) | (0.13) | |
| Return On Equity | (0.39) | (0.38) |
Things to note about Emergent Biosolutions performance evaluation
Checking the ongoing alerts about Emergent Biosolutions for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Emergent Biosolutions help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Emergent Biosolutions generated a negative expected return over the last 90 days | |
| Emergent Biosolutions has high historical volatility and very poor performance | |
| The company reported the last year's revenue of 1.01 B. Reported Net Loss for the year was (190.6 M) with profit before taxes, overhead, and interest of 290.1 M. | |
| About 58.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Benign Growth For Emergent BioSolutions Inc. Underpins Stocks 31 percent Plummet |
- Analyzing Emergent Biosolutions' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Emergent Biosolutions' stock is overvalued or undervalued compared to its peers.
- Examining Emergent Biosolutions' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Emergent Biosolutions' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Emergent Biosolutions' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Emergent Biosolutions' stock. These opinions can provide insight into Emergent Biosolutions' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Emergent Stock Analysis
When running Emergent Biosolutions' price analysis, check to measure Emergent Biosolutions' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Emergent Biosolutions is operating at the current time. Most of Emergent Biosolutions' value examination focuses on studying past and present price action to predict the probability of Emergent Biosolutions' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Emergent Biosolutions' price. Additionally, you may evaluate how the addition of Emergent Biosolutions to your portfolios can decrease your overall portfolio volatility.